COVID-19
Conditions
Brief summary
This research is a study that compares the administration of N-acetylcysteine at various doses with the outcomes of COVID-19 patients, namely the neutrophil-to-lymphocyte ratio and length of stay.
Detailed description
This research was an observational analytic cohort retrospective study in which the subjects were moderate degree COVID-19 inpatients in Sebelas Maret University Hospital divided into four groups. The control group K0 received standard therapy without NAC, while the treatment group K1 received NAC injections of 1200mg/day, K2 NAC tablets 3x400mg/day, and K3 NAC tablets 3x200mg/day. Different tests using Way ANOVA and LSD or Kruskal-Wallis and Mann-Whitney.
Interventions
DRUGN-acetyl cysteine
N-acetyl cysteine dosage 600 mg and 1200 mg
Sponsors
Universitas Sebelas Maret
Study design
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
This study used N acetyl cysteine capsules and placebo, which were made similar in shape; researchers and patients did not know who was getting the drug or placebo.
Intervention model description
This research was an observational analytic cohort retrospective study in which the subjects were moderate degree COVID-19 inpatients in Sebelas Maret University Hospital divided into four groups. The control group K0 received standard therapy without NAC, while the treatment group, K1, received NAC injections of 1200mg/day, K2 NAC tablets 3x400mg/day, and K3 NAC tablets 3x200mg/day. Different tests using Way ANOVA and LSD or Kruskal-Wallis and Mann-Whitney.
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* moderate or severe grade confirmed COVID-19 (patients with symptoms and radiological examination showing pneumonia with or without signs of severe pneumonia: SpO2\<90%, respiratory rate\>30x/min, and severe respiratory distress) who were admitted to UNS Hospital and age 18-60 years old
Exclusion criteria
* patients who died during the treatment period
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Neutrophil to lymphocyte ratio | Change of Neutrophil to lymphocyte ratio at 7 day | Neutrophil to lymphocyte ratio |
| Length of stay | From date of randomization until the date of return from hospital | Length of stay |
Countries
Indonesia
Outcome results
None listed